Growth in Royalty and Milestone Income from Out-Licensed Products
First written in FY2023-Q2. 7 of 10 entries say "Advanced", first in FY2023-Q3. Latest entry: 2026-07-31.
0 other companies' latest entry also says "Advanced".
- 2026-07-31AdvancedEarnings
「The anti-APRIL antibody VOYXACT, launched in 2025, and increased royalty income」
The company stated that the launch of VOYXACT and increased royalty income contributed to higher revenue in the medical-related business. - FY2026-H1AdvancedAnnual report
「License and royalty income was ¥108,740 million in the healthcare business, ¥84 million in the nutraceuticals-related business, and ¥24 million in other businesses, for a total of ¥108,851 million.」
Total license and royalty income increased from ¥55,690 million in the same period of the previous year to ¥108,851 million, contributing to growth in revenue from the healthcare business. - FY2025AdvancedAnnual report
「License and royalty income in the healthcare business was ¥157,818 million, up from ¥120,881 million in the same quarter of the previous year.」
License and royalty income from derived products and other sources in the healthcare business was ¥157,818 million, up from ¥120,881 million in the previous fiscal year. - FY2025-H1AdvancedAnnual report
「License and royalty income was ¥55,574 million in the healthcare business, ¥85 million in the nutraceuticals-related business, and ¥27 million in other businesses, for a total of ¥55,690 million.」
Total license and royalty income increased from ¥45,210 million in the same period of the previous year to ¥55,690 million, contributing to revenue in the healthcare business. - FY2024AdvancedAnnual report
「License and royalty income in the healthcare business was ¥120,881 million, up from ¥98,468 million in the same quarter of the previous year.」
License and royalty income from derived products and other sources in the healthcare business increased to ¥120,881 million, contributing to business profit and revenue growth. - FY2024-H1Continued decline in license and royalty incomeAnnual report
「License and royalty income was ¥45,014 million in the healthcare business, ¥121 million in the nutraceuticals-related business, and ¥73 million in other businesses, for a total of ¥45,210 million.」
Total license and royalty income was ¥45,210 million, down from ¥48,389 million in the same period of the previous year. - FY2024-Q1Decline in license and royalty incomeAnnual report
「License and royalty income 17,439 29 1 30 17,499」
Total license and royalty income, including the healthcare business, was ¥17,499 million, down from ¥22,648 million in the same quarter of the previous year. - FY2023AdvancedAnnual report
「License and royalty income in the healthcare business was ¥98,216 million, up from ¥41,235 million in the same quarter of the previous year.」
License and royalty income in the healthcare business was ¥98,216 million, up from ¥41,235 million in the previous fiscal year. - FY2023-Q3AdvancedAnnual report
「License and royalty income in the healthcare business was ¥71,333 million, up from ¥21,146 million in the same quarter of the previous year.」
License and royalty income in the healthcare business was ¥71,333 million, a substantial increase from ¥21,146 million in the same quarter of the previous year. Growth in royalty and milestone income from derived products and other sources is driving results. - FY2023-Q2First statedAnnual report
「This was attributable to growth in royalty and milestone income from the four global products and derived products, which drove results.」
For the first time, growth in royalty and milestone income from derived products was identified separately, alongside the four global products, as a factor behind increases in the healthcare business and consolidated revenue.